ArticleInternational journal of surgery (London, England)2026
A multicenter parallel-group double-blind randomized placebo-controlled phase III clinical trial of generic aprepitant QLG2174 for the prevention of postoperative nausea and vomiting.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative nausea and vomiting (PONV), a common gastrointestinal disorder following surgery, primarily occurs within 6-24 hours postoperatively, with an incidence rate of approximately 30% in general surgical patients. QLG2174 (generic aprepitant) is a neurokinin-1 (NK-1) receptor antagonist exerting antiemetic effects by blocking the binding of substance P to NK-1 receptors. This study aimed to evaluate the efficacy and safety of QLG2174 for preventing PONV in Chinese patients. Materials and methods: This was a multi-center, parallel-group, double-blind, randomized, placebo-controlled, phase 3 clinical trial. Patients with ≥2 PONV risk factors and scheduled for elective laparoscopic gynecologic or abdominal surgery under general anesthesia were randomized 1:1 to receive either QLG2174 32 mg or placebo via intravenous injection within 30 seconds before anesthesia induction. The primary efficacy endpoint was the proportion of patients achieving complete response (CR, defined as no vomiting and no rescue therapy use) within 24 hours postoperatively. Results: A total of 515 patients were enrolled. The CR rate within 24 hours postoperatively was significantly higher in the QLG2174 group compared with that in the placebo group [70.7% (181/256) versus 44.0% (114/259); adjusted rate difference 26.6% (95% confidence interval, 18.4-34.7), Conclusion: QLG2174 significantly increased CR rate compared with placebo and demonstrated promising efficacy in preventing PONV in patients scheduled for elective laparoscopic surgery under general anesthesia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.